• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

新型联合疗法治疗广泛耐药性坏死性肺炎合并脓胸：一例报告

Novel Combination Therapy for Extensively Drug-Resistant Necrotizing Pneumonia Complicated by Empyema: A Case Report.

作者信息

Holger Dana J, Kunz Coyne Ashlan J, Zhao Jing J, Sandhu Avnish, Salimnia Hossein, Rybak Michael J

机构信息

Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.

Department of Pharmacy, Harper University Hospital, Detroit Medical Center, Detroit, Michigan, USA.

出版信息

Open Forum Infect Dis. 2022 Mar 5;9(4):ofac092. doi: 10.1093/ofid/ofac092. eCollection 2022 Apr.

DOI:10.1093/ofid/ofac092
PMID:35350174
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8946682/
Abstract

We report our clinical and laboratory experience treating a 50-year-old patient who was critically ill with extensively drug-resistant necrotizing pneumonia complicated by empyema in Detroit, Michigan. A precision medicine approach using whole-genome sequencing, susceptibility testing, and synergy analysis guided the selection of rational combination antimicrobial therapy.

摘要

我们报告了我们对一名50岁患者的临床和实验室治疗经验，该患者在密歇根州底特律患有广泛耐药性坏死性肺炎并伴有脓胸，病情危急。采用全基因组测序、药敏试验和协同分析的精准医学方法指导了合理联合抗菌治疗的选择。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af1d/8946682/9ef38a9f0f70/ofac092_fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af1d/8946682/5e2d7221c886/ofac092_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af1d/8946682/9ef38a9f0f70/ofac092_fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af1d/8946682/5e2d7221c886/ofac092_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af1d/8946682/9ef38a9f0f70/ofac092_fig2.jpg

相似文献

1
Novel Combination Therapy for Extensively Drug-Resistant Necrotizing Pneumonia Complicated by Empyema: A Case Report.新型联合疗法治疗广泛耐药性坏死性肺炎合并脓胸：一例报告
Open Forum Infect Dis. 2022 Mar 5;9(4):ofac092. doi: 10.1093/ofid/ofac092. eCollection 2022 Apr.
2
Comparison of the clinical efficacy between tigecycline plus extended-infusion imipenem and sulbactam plus imipenem against ventilator-associated pneumonia with pneumonic extensively drug-resistant Acinetobacter baumannii bacteremia, and correlation of clinical efficacy with in vitro synergy tests.替加环素联合延长输注亚胺培南与舒巴坦联合亚胺培南治疗呼吸机相关性肺炎合并泛耐药鲍曼不动杆菌菌血症的临床疗效比较及体外协同试验与临床疗效的相关性分析。
J Microbiol Immunol Infect. 2016 Dec;49(6):924-933. doi: 10.1016/j.jmii.2015.06.009. Epub 2015 Aug 14.
3
Sulbactam-durlobactam for the treatment of Acinetobacter baumannii-calcoaceticus complex.舒巴坦-他唑巴坦治疗鲍曼不动杆菌-醋酸钙不动杆菌复合体。
Expert Rev Anti Infect Ther. 2024 Nov;22(11):925-934. doi: 10.1080/14787210.2024.2400703. Epub 2024 Sep 8.
4
In vitro activity of sulbactam/durlobactam against global isolates of carbapenem-resistant Acinetobacter baumannii.多利培南/舒巴坦对全球碳青霉烯类耐药鲍曼不动杆菌分离株的体外活性。
J Antimicrob Chemother. 2020 Sep 1;75(9):2616-2621. doi: 10.1093/jac/dkaa208.
5
Activity of Sulbactam-Durlobactam against Acinetobacter baumannii- Complex Isolates Collected Globally in 2016 and 2017.舒巴坦-多利布坦对 2016 年和 2017 年全球收集的鲍曼不动杆菌复合菌株的活性。
Antimicrob Agents Chemother. 2020 Mar 24;64(4). doi: 10.1128/AAC.02534-19.
6
synergistic activity of the sulbactam/avibactam combination against extensively drug-resistant .舒巴坦/阿维巴坦合剂对广泛耐药的协同活性。
J Med Microbiol. 2020 Jul;69(7):928-931. doi: 10.1099/jmm.0.001211.
7
In vitro activity of sulbactam/durlobactam against clinical isolates of Acinetobacter baumannii collected in China.舒巴坦/度洛巴坦对中国收集的鲍曼不动杆菌临床分离株的体外活性
J Antimicrob Chemother. 2020 Jul 1;75(7):1833-1839. doi: 10.1093/jac/dkaa119.
8
Combination carbapenem-sulbactam therapy for critically ill patients with multidrug-resistant Acinetobacter baumannii bacteremia: four case reports and an in vitro combination synergy study.碳青霉烯类-舒巴坦联合疗法治疗多重耐药鲍曼不动杆菌血症的重症患者：4例病例报告及体外联合协同研究
Pharmacotherapy. 2007 Nov;27(11):1506-11. doi: 10.1592/phco.27.11.1506.
9
[In vitro synergistic activity of sulbactam in combination with imipenem, meropenem and cefoperazone against carbapenem-resistant Acinetobacter baumannii isolates].舒巴坦与亚胺培南、美罗培南和头孢哌酮联合对耐碳青霉烯类鲍曼不动杆菌分离株的体外协同活性
Mikrobiyol Bul. 2014 Apr;48(2):311-5. doi: 10.5578/mb.7104.
10
Enhanced bacterial killing with colistin/sulbactam combination against carbapenem-resistant Acinetobacter baumannii.多黏菌素 E/舒巴坦联合应用增强对碳青霉烯类耐药鲍曼不动杆菌的杀菌作用。
Int J Antimicrob Agents. 2021 Feb;57(2):106271. doi: 10.1016/j.ijantimicag.2020.106271. Epub 2020 Dec 23.

引用本文的文献

1
treatment strategies: a review of therapeutic challenges and considerations.治疗策略：治疗挑战与考量综述
Antimicrob Agents Chemother. 2025 Aug 6;69(8):e0106324. doi: 10.1128/aac.01063-24. Epub 2025 Jul 9.
2
The Multifaceted Landscape of Healthcare-Associated Infections Caused by Carbapenem-Resistant .耐碳青霉烯类药物引起的医疗保健相关感染的多方面情况
Microorganisms. 2025 Apr 5;13(4):829. doi: 10.3390/microorganisms13040829.
3
Sulbactam for carbapenem-resistant infections: a literature review.舒巴坦用于耐碳青霉烯类感染：一项文献综述。

本文引用的文献

1
Infectious Diseases Society of America Guidance on the Treatment of AmpC β-Lactamase-Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections.美国传染病学会关于治疗产 AmpC β-内酰胺酶肠杆菌科、耐碳青霉烯类鲍曼不动杆菌和嗜麦芽窄食单胞菌感染的指南。
Clin Infect Dis. 2022 Jul 6;74(12):2089-2114. doi: 10.1093/cid/ciab1013.
2
Extensively Drug-Resistant Acinetobacter baumannii Nosocomial Pneumonia Successfully Treated with a Novel Antibiotic Combination.新型抗生素联合治疗广泛耐药鲍曼不动杆菌医院获得性肺炎的疗效观察。
Antimicrob Agents Chemother. 2021 Oct 18;65(11):e0092421. doi: 10.1128/AAC.00924-21. Epub 2021 Aug 9.
3
JAC Antimicrob Resist. 2025 Apr 12;7(2):dlaf055. doi: 10.1093/jacamr/dlaf055. eCollection 2025 Apr.
4
The challenges of difficult-to-treat infections.难以治疗的感染所带来的挑战。
Clin Microbiol Rev. 2024 Dec 10;37(4):e0009324. doi: 10.1128/cmr.00093-24. Epub 2024 Nov 18.
5
Treatment of infections caused by carbapenem-resistant .治疗耐碳青霉烯类抗生素的感染。
Front Cell Infect Microbiol. 2024 Jul 18;14:1395260. doi: 10.3389/fcimb.2024.1395260. eCollection 2024.
6
Antibiotic Treatment of Carbapenem-Resistant Infections in View of the Newly Developed β-Lactams: A Narrative Review of the Existing Evidence.基于新研发的β-内酰胺类药物视角下对碳青霉烯类耐药感染的抗生素治疗：现有证据的叙述性综述
Antibiotics (Basel). 2024 May 29;13(6):506. doi: 10.3390/antibiotics13060506.
7
Clinical Outcomes for Patients With Monomicrobial vs Polymicrobial Complex Infections Treated With Sulbactam-Durlobactam or Colistin: A Subset Analysis From a Phase 3 Clinical Trial.用舒巴坦-度洛巴坦或多粘菌素治疗单微生物与多微生物复杂感染患者的临床结局：一项3期临床试验的亚组分析
Open Forum Infect Dis. 2024 Mar 20;11(4):ofae140. doi: 10.1093/ofid/ofae140. eCollection 2024 Apr.
8
Cefiderocol and Sulbactam-Durlobactam against Carbapenem-Resistant .头孢地尔和舒巴坦-度洛巴坦治疗耐碳青霉烯类感染
Antibiotics (Basel). 2023 Dec 14;12(12):1729. doi: 10.3390/antibiotics12121729.
9
Eravacycline, the first four years: health outcomes and tolerability data for 19 hospitals in 5 U.S. regions from 2018 to 2022.依拉环素：四年经验——2018 年至 2022 年来自美国五个地区 19 家医院的健康结局和耐受性数据。
Microbiol Spectr. 2024 Jan 11;12(1):e0235123. doi: 10.1128/spectrum.02351-23. Epub 2023 Nov 29.
10
In Vivo Emergence of Pandrug-Resistant Strain: Comprehensive Resistance Characterization and Compassionate Use of Sulbactam-Durlobactam.全耐药菌株的体内出现：舒巴坦-度洛巴坦的全面耐药性特征及同情用药
Open Forum Infect Dis. 2023 Oct 6;10(10):ofad504. doi: 10.1093/ofid/ofad504. eCollection 2023 Oct.
Antibacterial Activity of Cefiderocol against Multidrug-Resistant Acinetobacter baumannii.
头孢地尔罗酯对多重耐药鲍曼不动杆菌的抗菌活性。
Antimicrob Agents Chemother. 2021 Aug 17;65(9):e0264620. doi: 10.1128/AAC.02646-20.
4
A comprehensive and contemporary "snapshot" of β-lactamases in carbapenem resistant Acinetobacter baumannii.碳青霉烯类耐药鲍曼不动杆菌中β-内酰胺酶的全面和现代“快照”。
Diagn Microbiol Infect Dis. 2021 Feb;99(2):115242. doi: 10.1016/j.diagmicrobio.2020.115242. Epub 2020 Oct 16.
5
Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial.头孢地尔与大剂量延长输注美罗培南治疗革兰阴性菌医院获得性肺炎（APEKS-NP）：一项随机、双盲、3期、非劣效性试验。
Lancet Infect Dis. 2021 Feb;21(2):213-225. doi: 10.1016/S1473-3099(20)30731-3. Epub 2020 Oct 12.
6
Activity of Sulbactam-Durlobactam against Acinetobacter baumannii- Complex Isolates Collected Globally in 2016 and 2017.舒巴坦-多利布坦对 2016 年和 2017 年全球收集的鲍曼不动杆菌复合菌株的活性。
Antimicrob Agents Chemother. 2020 Mar 24;64(4). doi: 10.1128/AAC.02534-19.
7
Activity of Eravacycline against Gram-Negative Bacilli Isolated in Clinical Laboratories Worldwide from 2013 to 2017.2013 年至 2017 年全球临床实验室分离的革兰氏阴性杆菌对依拉环素的活性。
Antimicrob Agents Chemother. 2020 Feb 21;64(3). doi: 10.1128/AAC.01699-19.
8
IGNITE4: Results of a Phase 3, Randomized, Multicenter, Prospective Trial of Eravacycline vs Meropenem in the Treatment of Complicated Intraabdominal Infections.IGNITE4 研究：依拉环素对比美罗培南治疗复杂性腹腔内感染的 3 期、随机、多中心、前瞻性试验结果。
Clin Infect Dis. 2019 Aug 30;69(6):921-929. doi: 10.1093/cid/ciy1029.
9
Evaluation of dalbavancin alone and in combination with β-lactam antibiotics against resistant phenotypes of Staphylococcus aureus.评估达巴万星单药治疗和联合β-内酰胺类抗生素治疗耐甲氧西林金黄色葡萄球菌耐药表型的疗效。
J Antimicrob Chemother. 2019 Jan 1;74(1):82-86. doi: 10.1093/jac/dky376.
10
Plasma and Intrapulmonary Concentrations of ETX2514 and Sulbactam following Intravenous Administration of ETX2514SUL to Healthy Adult Subjects.健康成年受试者静脉注射 ETX2514SUL 后 ETX2514 和舒巴坦的血浆和肺内浓度。
Antimicrob Agents Chemother. 2018 Oct 24;62(11). doi: 10.1128/AAC.01089-18. Print 2018 Nov.